myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and…
myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL…
myCare-021-02 study discovers patient-specific resistance mechanisms that can inform…
myCare-021-04 study finds genetic signatures associated with 100% remission rate from…
Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and…
myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of…
myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of…
Study Uses NGS Data with Biosimulation to Predict Drug Response in AML and MDS…
New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration…
Analysis Uncovered Possible Mechanisms for AZA Resistance that could be Targeted to…
Prospective Study Successfully Identified Mechanisms for AML…
ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in…
Leading Precision Medicine Company Adds to Prestigious Board of Directors, which…
Former CEO of ASCO Elected to Board of Leading Precision Medicine Company
…
LONDON—As tuberculosis drug sensitivity and resistance reaches epidemic proportions in…
The Wellcome Trust has supported a collaboration between AstraZeneca and Cellworks to…
AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome…
Drug development programs today have a 5% to 10% probability of success. Almost half…
The outlook for the drug industry continues to remain bleak in context of productivity…
With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks…
As the first part of this series began with the single word, "Viagra," this…